Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

43.96 +0.54 (+1.24%)

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

October 23, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis ranked #1 on Science’s Top Employers list

October 22, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

This beaten-down biotech has a better story than its stock chart suggests.

Via The Motley Fool

Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates ↗

July 29, 2026

Via Chartmill

Topics Earnings

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

October 20, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

October 16, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Via The Motley Fool

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Via The Motley Fool

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

September 23, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

September 22, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook ↗

September 20, 2026

Shares of Ionis are down more than 40% so far this year.

Via The Motley Fool

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks ↗

September 19, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while...

Via MarketBeat

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗

September 14, 2026

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

Via The Motley Fool

Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. ↗

September 09, 2026

Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks.

Via The Motley Fool

Stay updated with the stocks that are on the move in today's after-hours session. ↗

September 04, 2026

Via Chartmill

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

September 04, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗

September 04, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive...

Via MarketBeat

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

September 03, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

September 03, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

This biotech stock looks like a great candidate to buy on the admittedly steep dip.

Via The Motley Fool

Breakfast News: A Conversation With Ionis CEO ↗

August 22, 2026

Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.

Via The Motley Fool

Topics ETFs World Trade

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

August 20, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

Via The Motley Fool

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗

August 14, 2026

A drug that didn't meet expectations in a trial is to blame.

Via The Motley Fool

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

August 08, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Ionis (IONS) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated.

Via The Motley Fool

Topics Earnings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

August 04, 2026

From Pomerantz LLP

Via GlobeNewswire

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? ↗

August 03, 2026

Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement.

Via The Motley Fool

Topics Regulatory Compliance

Ionis Pharmaceuticals Q2 Earnings Call Highlights ↗

July 29, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch...

Via MarketBeat

Topics Earnings

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

July 29, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.